Anzeige
Erschienen in:
01.05.2012 | Original Article
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
Erschienen in: Supportive Care in Cancer | Ausgabe 5/2012
Einloggen, um Zugang zu erhaltenAbstract
Purpose
This study sought to prospectively determine the frequency of delayed nausea and vomiting with oxaliplatin-based chemotherapy following day 1 prophylaxis with a 5-HT-3 receptor antagonist and dexamethasone.
Methods
Patients with colon cancer, ≥ age 18, with a performance status ≤2, receiving oxaliplatin (85–100 mg/m2) as part of a standard folinic acid, 5-flourouracil, oxaliplatin regimen for the first time were eligible. All patients received a 5-HT3 receptor antagonist and dexamethasone 20 mg on day 1 prior to oxaliplatin. No routine prophylaxis for delayed emesis was given. Antiemetic outcome was recorded in patient-completed diaries for the 120-h study period following oxaliplatin administration. Primary endpoint was frequency of delayed (24–120 h) emesis (vomiting/retching).
Results
Forty-one patients were enrolled and 39 are evaluable. Median age was 70 (34–85) and the female/male ratio was 20:19. Four patients (10%) experienced vomiting or retching during the delayed period. One patient vomited during the first 24 h after oxaliplatin. The overall (120 h) no emesis rate was 87% (34/39). Twenty-one patients (54%) developed delayed nausea. Nine patients had moderate or severe nausea. Eighteen patients (46%) took rescue antiemetics during the delayed period. Delayed and overall complete response (no emesis or use of rescue antiemetics) rates were 54% and 49%, respectively.
Conclusions
The use of a 5-HT3 antagonist and dexamethasone prior to oxaliplatin results in excellent control of nausea and vomiting (CR—90%) during the 24 h after chemotherapy. However, without further antiemetic treatment, complete response in the delayed period decreased to 54%. This study supports the need for routine antiemetic prophylaxis for delayed nausea and vomiting following oxaliplatin-based chemotherapy.